Astec LifeSciences Limited — Board Meeting, 27-01-2025: Outcome of Board Meeting

The Board of Directors has convened and approved the unaudited financial results for the quarter and nine months period ended 31st December 2024. The consolidated total income reached ₹96.5 crore, while the standalone total income was ₹96.1 crore. Profit after tax for the consolidated group was a loss of ₹40.4 crore, and for the standalone entity, the loss was ₹40.4 crore as well. Additionally, the board has approved an equity investment of ₹3.75 crore in a Special Purpose Vehicle aimed at generating solar power. Mr. R. R. Govindan has been re-appointed as a Non-Executive & Independent Director for a second term, subject to shareholder approval.